sacituzumab,Pembrolizumab,Avelumab,Zimberelimab,Domvanalimab,enfortumab,cisplatin,carboplatin,gemcitabine,Erdafitinib,Vinflunine,Docetaxel
Gilead,Merck,Pfizer,Arcus Biosciences,Otsuka,Astellas,Seagen,Janssen,pierre fabre
['muc ,(-much)']
 discussant: 2/3 of pts w/#muc don t receive #2l therapy, fgfr alt freq higher in low-grade tumors and diff in #fgfr alts b/t #utuc &amp; #ubuc (work by ), believes right now best way to select for #3l therapy is by toxicity/comorbidities #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope